This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davis, P. D. Articles by Hill, S. A. Search for Related Content PubMed PubMed Citation Articles by Davis, P. D. Articles by Hill, S. A.

ZD6126

A Novel Vascular-targeting Agent That Causes Selective Destruction of Tumor Vasculature

Angiogene Pharmaceuticals Ltd., Oxford Science Park, Oxford, OX4 4GA [P. D. D., G. J. D.]; AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG [D. C. B.]; and Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex, HA6 2JR [S. M. G., G. M. T., A. L. H., M. A. N., J. N., M. R. L. S., D. J. C., S. A. H.], United Kingdom

Physiological differences between tumor and normal vasculature provide a target for drug discovery. In particular, the immature nature of tumor vasculature may render it intrinsically sensitive to disruption by agents affecting the endothelial cell cytoskeleton, including tubulin-binding agents. In this article, we report the synthesis of a water-soluble phosphate prodrug, ZD6126, of the tubulin-binding agent N-acetylcolchinol. In vitro studies demonstrate the comparative tubulin-binding properties of the prodrug and active drug, and show the induction of pronounced, reversible changes in endothelial cell morphology at subcytotoxic doses. Neither ZD6126 nor N-acetylcolchinol showed effects on the growth of human umbilical vein endothelial cells at concentrations below 100 µM. In contrast, changes in endothelial cell morphology were seen at much lower, noncytotoxic concentrations (0.1 µM) of ZD6126 and more pronounced effects were seen in proliferating versus confluent endothelial cell cultures. In vivo studies were carried out using a murine tumor model (CaNT) with single administration of a dose well below the maximum tolerated dose. These studies showed a large reduction in vascular volume, induction of extensive necrosis in tumors, and a reduced tumor cell yield in a clonal excision assay, consistent with vascular rather than cytotoxic effects. A viable rim of tumor remained after single-dose administration and minimal growth delay was observed. However, well-tolerated, multiple administration regimens led to pronounced tumor-growth delay. In the human xenograft FaDu, the growth delay given by a single dose of paclitaxel was enhanced by combination with a single dose of ZD6126, and the growth delay given by the combination was greater than the sum of the growth delays from the individual treatments. These findings show that ZD6126 is a promising antivascular agent for the treatment of solid tumors.

This article has been cited by other articles:

				E. Ito, K. W. Yip, D. Katz, S. B. Fonseca, D. W. Hedley, S. Chow, G. W. Xu, T. E. Wood, C. Bastianutto, A. D. Schimmer, et al. Potential Use of Cetrimonium Bromide as an Apoptosis-Promoting Anticancer Agent for Head and Neck Cancer Mol. Pharmacol., November 1, 2009; 76(5): 969 - 983. [Abstract] [Full Text] [PDF]

				E. L. Schwartz Antivascular Actions of Microtubule-Binding Drugs Clin. Cancer Res., April 15, 2009; 15(8): 2594 - 2601. [Abstract] [Full Text] [PDF]

				M. H. A. M. Fens, E. Mastrobattista, A. M. de Graaff, F. M. Flesch, A. Ultee, J. T. Rasmussen, G. Molema, G. Storm, and R. M. Schiffelers Angiogenic endothelium shows lactadherin-dependent phagocytosis of aged erythrocytes and apoptotic cells Blood, May 1, 2008; 111(9): 4542 - 4550. [Abstract] [Full Text] [PDF]

				S. Gould, F. R. Westwood, J. O. Curwen, S. E. Ashton, D. W. Roberts, S. C. Lovick, and A. J. Ryan Effect of Pretreatment With Atenolol and Nifedipine on ZD6126-Induced Cardiac Toxicity in Rats J Natl Cancer Inst, November 21, 2007; 99(22): 1724 - 1728. [Abstract] [Full Text] [PDF]

				T. J. Kim, M. Ravoori, C. N. Landen, A. A. Kamat, L. Y. Han, C. Lu, Y. G. Lin, W. M. Merritt, N. Jennings, W. A. Spannuth, et al. Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma Cancer Res., October 1, 2007; 67(19): 9337 - 9345. [Abstract] [Full Text] [PDF]

				J. Gamrekelashvili, C. Kruger, R. von Wasielewski, M. Hoffmann, K. M. Huster, D. H. Busch, M. P. Manns, F. Korangy, and T. F. Greten Necrotic Tumor Cell Death In Vivo Impairs Tumor-Specific Immune Responses J. Immunol., February 1, 2007; 178(3): 1573 - 1580. [Abstract] [Full Text] [PDF]

				A. M. Iga, S. Sarkar, K. M. Sales, M. C. Winslet, and A. M. Seifalian Quantitating Therapeutic Disruption of Tumor Blood Flow with Intravital Video Microscopy Cancer Res., December 15, 2006; 66(24): 11517 - 11519. [Abstract] [Full Text] [PDF]

				M. R. Horsman and D. W. Siemann Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies Cancer Res., December 15, 2006; 66(24): 11520 - 11539. [Abstract] [Full Text] [PDF]

				K. W. Yip, X. Mao, P.Y. B. Au, D. W. Hedley, S. Chow, S. Dalili, J. D. Mocanu, C. Bastianutto, A. Schimmer, and F.-F. Liu Benzethonium Chloride: A Novel Anticancer Agent Identified by Using a Cell-Based Small-Molecule Screen. Clin. Cancer Res., September 15, 2006; 12(18): 5557 - 5569. [Abstract] [Full Text] [PDF]

				L. V. Beerepoot, S. A. Radema, E. O. Witteveen, T. Thomas, C. Wheeler, S. Kempin, and E. E. Voest Phase I Clinical Evaluation of Weekly Administration of the Novel Vascular-Targeting Agent, ZD6126, in Patients With Solid Tumors J. Clin. Oncol., April 1, 2006; 24(10): 1491 - 1498. [Abstract] [Full Text] [PDF]

				J. V. Skliarenko, S. J. Lunt, M. L. Gordon, A. Vitkin, M. Milosevic, and R. P. Hill Effects of the Vascular Disrupting Agent ZD6126 on Interstitial Fluid Pressure and Cell Survival in Tumors Cancer Res., February 15, 2006; 66(4): 2074 - 2080. [Abstract] [Full Text] [PDF]

				A. P. Hall, F. R. Westwood, and P. F. Wadsworth Review of the Effects of Anti-Angiogenic Compounds on the Epiphyseal Growth Plate Toxicol Pathol, February 1, 2006; 34(2): 131 - 147. [Abstract] [Full Text] [PDF]

				P. Beaudry, J. Force, G. N. Naumov, A. Wang, C. H. Baker, A. Ryan, S. Soker, B. E. Johnson, J. Folkman, and J. V. Heymach Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity Clin. Cancer Res., May 1, 2005; 11(9): 3514 - 3522. [Abstract] [Full Text] [PDF]

				G. Taraboletti, G. Micheletti, R. Dossi, P. Borsotti, M. Martinelli, F. Fiordaliso, A. J. Ryan, and R. Giavazzi Potential Antagonism of Tubulin-Binding Anticancer Agents in Combination Therapies Clin. Cancer Res., April 1, 2005; 11(7): 2720 - 2726. [Abstract] [Full Text] [PDF]

				P. R. Wachsberger, R. Burd, N. Marero, C. Daskalakis, A. Ryan, P. McCue, and A. P. Dicker Effect of the Tumor Vascular-Damaging Agent, ZD6126, on the Radioresponse of U87 Glioblastoma Clin. Cancer Res., January 15, 2005; 11(2): 835 - 842. [Abstract] [Full Text] [PDF]

				H. Goto, S. Yano, Y. Matsumori, H. Ogawa, D. C. Blakey, and S. Sone Sensitization of Tumor-Associated Endothelial Cell Apoptosis by the Novel Vascular-Targeting Agent ZD6126 in Combination with Cisplatin Clin. Cancer Res., November 15, 2004; 10(22): 7671 - 7676. [Abstract] [Full Text] [PDF]

				S. Kasibhatla, H. Gourdeau, K. Meerovitch, J. Drewe, S. Reddy, L. Qiu, H. Zhang, F. Bergeron, D. Bouffard, Q. Yang, et al. Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity Mol. Cancer Ther., November 1, 2004; 3(11): 1365 - 1374. [Abstract] [Full Text] [PDF]

				H. Gourdeau, L. Leblond, B. Hamelin, C. Desputeau, K. Dong, I. Kianicka, D. Custeau, C. Boudreau, L. Geerts, S.-X. Cai, et al. Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents Mol. Cancer Ther., November 1, 2004; 3(11): 1375 - 1384. [Abstract] [Full Text] [PDF]

				D. Raben, C. Bianco, V. Damiano, R. Bianco, D. Melisi, C. Mignogna, F. P. D'Armiento, L. Cionini, A. R. Bianco, G. Tortora, et al. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model Mol. Cancer Ther., August 1, 2004; 3(8): 977 - 983. [Abstract] [Full Text] [PDF]

				S. A. Horner, S. Gould, J. P. Noakes, N. J. Rattray, S. L. Allen, E. Zotova, and J. C. Arezzo Lack of neurotoxicity of the vascular targeting agent ZD6126 following repeated i.v. dosing in the rat Mol. Cancer Ther., July 1, 2004; 3(7): 783 - 791. [Abstract] [Full Text] [PDF]

				J. L. Evelhoch, P. M. LoRusso, Z. He, Z. DelProposto, L. Polin, T. H. Corbett, P. Langmuir, C. Wheeler, A. Stone, J. Leadbetter, et al. Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126 Clin. Cancer Res., June 1, 2004; 10(11): 3650 - 3657. [Abstract] [Full Text] [PDF]

				P. E. Thorpe Vascular Targeting Agents as Cancer Therapeutics Clin. Cancer Res., January 15, 2004; 10(2): 415 - 427. [Abstract] [Full Text] [PDF]

				Q.-T. Le and A. J. Giaccia Therapeutic Exploitation of the Physiological and Molecular Genetic Alterations in Head and Neck Cancer Clin. Cancer Res., October 1, 2003; 9(12): 4287 - 4295. [Abstract] [Full Text] [PDF]